ADMA Biologics, Inc. (ADMA) Stock Price

ADMAStock

$10.68−26.65%52W

Market Cap$2.39B

P/E16.28x

PEG Ratio—

Div yield—

Beta0.70

ADMA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-8.09%

Price vs S&P 500 (4W)13.69%

VGM Score59.16

P/E Ratio (Annual)16.28x

P/CF (Annual)47.47x

Book Value / Share (Quarterly)$1.81

P/TBV (Annual)9.11x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)49.04%

Cash Flow / Share (Quarterly)$0.52

Price vs S&P 500 (YTD)-53.37%

Gross Margin (TTM)64.71%

Net Profit Margin (TTM)32.98%

EPS (TTM)$0.71

10-Day Avg Trading Volume2.95M

EPS Excl Extra (TTM)$0.71

Revenue Growth (5Y)64.62%

EPS (Annual)$0.60

ROI (Annual)26.74%

Gross Margin (Annual)57.39%

Net Profit Margin (5Y Avg)-13.41%

Cash / Share (Quarterly)$0.60

P/E Basic Excl Extra (TTM)14.16x

Revenue Growth QoQ (YoY)1.98%

P/E Normalized (Annual)16.28x

ROA (Last FY)23.54%

Revenue Growth TTM (YoY)8.04%

EBITD / Share (TTM)$0.93

ROE (5Y Avg)-5.51%

Operating Margin (TTM)43.40%

Cash Flow / Share (Annual)$0.12

P/B Ratio5.86x

P/B Ratio (Quarterly)4.75x

Net Income / Employee (Annual)$227,100

EV / Revenue (TTM)4.79x

Net Interest Coverage (TTM)35.86x

ROA (TTM)26.58%

EPS Growth QoQ (YoY)19.33%

EV / EBITDA (TTM)11.02x

EPS Incl Extra (Annual)$0.60

Current Ratio (Annual)6.71x

Quick Ratio (Quarterly)3.62x

3-Month Avg Trading Volume2.91M

52-Week Price Return-26.65%

EV / Free Cash Flow (Annual)89.17x

P/E Incl Extra (TTM)14.16x

Revenue / Employee (TTM)$791,800

Tangible BV / Share (Quarterly)$1.81

P/S Ratio (Annual)4.69x

Asset Turnover (Annual)0.82x

52-Week High$20.46

Operating Margin (5Y Avg)-6.93%

EPS Excl Extra (Annual)$0.60

CapEx CAGR (5Y)12.45%

Tangible BV CAGR (5Y)40.88%

26-Week Price Return1.81%

Quick Ratio (Annual)3.63x

13-Week Price Return22.62%

Total Debt / Equity (Annual)0.15x

Current Ratio (Quarterly)6.97x

Enterprise Value$2.45B

Revenue / Share Growth (5Y)33.56%

Asset Turnover (TTM)0.81x

Book Value / Share Growth (5Y)18.97%

Revenue / Employee (Annual)$788,500

Inventory Turnover (Annual)1.15x

Pretax Margin (Annual)35.80%

Cash / Share (Annual)$0.37

3-Month Return Std Dev41.02%

Gross Margin (5Y Avg)33.70%

Net Income / Employee (TTM)$261,100

ROE (Last FY)30.78%

Net Interest Coverage (Annual)35.46x

EPS Basic Excl Extra (Annual)$0.60

P/FCF (TTM)20.39x

Receivables Turnover (TTM)4.13x

EV / Free Cash Flow (TTM)21.10x

Total Debt / Equity (Quarterly)0.48x

EPS Incl Extra (TTM)$0.71

Receivables Turnover (Annual)4.90x

ROI (TTM)30.10%

P/S Ratio (TTM)4.67x

Pretax Margin (5Y Avg)-15.38%

Revenue / Share (Annual)$2.08

Tangible BV / Share (Annual)$2.00

Forward P/E11.39x

Price vs S&P 500 (52W)-42.18%

P/E Ratio (TTM)14.16x

EPS Growth TTM (YoY)-16.60%

Year-to-Date Return-41.45%

5-Day Price Return4.91%

EPS Normalized (Annual)$0.60

ROA (5Y Avg)2.12%

Net Profit Margin (Annual)28.80%

Month-to-Date Return6.48%

Cash Flow / Share (TTM)$-0.07

EBITD / Share (Annual)$0.77

Operating Margin (Annual)36.87%

LT Debt / Equity (Annual)0.15x

P/CF (TTM)17.50x

ROI (5Y Avg)2.07%

P/E Excl Extra (TTM)14.16x

LT Debt / Equity (Quarterly)0.47x

EPS Basic Excl Extra (TTM)$0.71

P/TBV (Quarterly)4.76x

P/B Ratio (Annual)9.09x

Inventory Turnover (TTM)0.84x

Pretax Margin (TTM)42.26%

Book Value / Share (Annual)$2.01

Price vs S&P 500 (13W)19.93%

Beta0.70x

P/FCF (Annual)86.97x

Revenue / Share (TTM)$2.22

ROE (TTM)39.59%

52-Week Low$7.21

vGradeC

gGradeC

mGradeB

vgmGradeC

ADMA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.16	$0.17	+3.53%(+$0.01)
Q1 2026	May 6, 2026	$0.20	$0.17	-15.25%(-$0.03)
Q4 2025	Feb 25, 2026	$0.20	$0.22	+7.85%(+$0.02)
Q3 2025	Nov 5, 2025	$0.15	$0.16	+2.59%(+$0.00)
Q2 2025	Aug 6, 2025	$0.14	$0.14	+7.41%(+$0.01)

ADMA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	B	168.6x	-19.0%	—	—	$17.17

About ADMA Biologics, Inc.

ADMA Biologics manufactures and markets plasma-derived immunoglobulin (IG) and intravenous immunoglobulin (IVIG) products for immunodeficient patients and those at risk for infectious diseases. The company operates through ADMA BioManufacturing, its primary revenue source, and Plasma Collection Centers, supplemented by laboratory and contract manufacturing services. It also sells plasma-derived intermediate fractions generated from its FDA-approved manufacturing process. The company derives substantially all revenue from the United States market.